AI in Healthcare and Digital Health Today—March 23, 2026
This week’s AI in Healthcare and Digital Health update highlights…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause Professional…
Lucid Diligence Brief: Waker BioScience Series A in CGT
Lucid Diligence Brief: Waker BioScience Series A in CGT Professional audiences…
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing partnership to advance CLG-001
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing…
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing…
Lucid Diligence Brief: AAVantgarde Bio $141M Series B
Lucid Diligence Brief: AAVantgarde Bio $141M Series B Professional audiences…
Cell and Gene Therapy Clinical Trials 2025 Edition
Introduction Cell and gene therapy (CGT) represents a groundbreaking frontier…
Cell and Gene Therapy Clinical Trials – 2024 Edition
Gene therapy clinical trials promise transformative breakthroughs in treating…
How a leading Biotech company supported its go-/no-go decision in the ophthalmology gene therapy (GT) space through a workshop.
The Challenge: Uncovering perceptions of GT in ophthalmology. LucidQuest…
How we helped a Top-10 BioPharma company enhance its strategic decision-making in the Sickle Cell Disease space.
The challenge: To map the competitive landscape in Cell and Gene Therapy for…
How LucidQuest insights helped a global leader in the Hemophilia space with its branding and positioning strategy.
The Challenge: To track the novel treatments’ (including gene and RNA…